China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio’s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT. These products will be exclusively promoted and marketed by Baheal upon regulatory approval in mainland China. The partnership is set to continue until December 31, 2033, with Ruidio paying Baheal service fees throughout the cooperation period.
Significance of Ruidio’s Radiopharmaceuticals and Imaging Equipment
99mTc-3PRGD2, a radioactive drug conjugate (RDC) targeting integrin, is the first Category 1 drug for nuclear medicine radiation diagnosis in China and the world’s first broad-spectrum tumor imaging agent for SPECT imaging. It has the ability to target integrin in tumor neovascularization αvβ3 receptors, allowing for earlier and more accurate diagnosis of benign, malignant, and lymph node metastasis of tumor tissue. Other products in Ruidio’s pipeline, such as 99mTc HP Ark2 for screening HER2 positive tumor patients and guiding treatment, 99mTc POFAP for SPECT imaging, and medical imaging SPECT-CT series devices, are yet to enter clinical trials.- Flcube.com
